Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy.
allogeneic immunotherapy
cancer
natural killer (NK) cells
pluripotent stem cells
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
29 04 2021
29 04 2021
Historique:
received:
01
04
2021
revised:
27
04
2021
accepted:
27
04
2021
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
25
2
2023
Statut:
epublish
Résumé
Natural killer (NK) cells are potent innate immune system effector lymphocytes armed with multiple mechanisms for killing cancer cells. Given the dynamic roles of NK cells in tumor surveillance, they are fast becoming a next-generation tool for adoptive immunotherapy. Many strategies are being employed to increase their number and improve their ability to overcome cancer resistance and the immunosuppressive tumor microenvironment. These include the use of cytokines and synthetic compounds to bolster propagation and killing capacity, targeting immune-function checkpoints, addition of chimeric antigen receptors (CARs) to provide cancer specificity and genetic ablation of inhibitory molecules. The next generation of NK cell products will ideally be readily available as an "off-the-shelf" product and stem cell derived to enable potentially unlimited supply. However, several considerations regarding NK cell source, genetic modification and scale up first need addressing. Understanding NK cell biology and interaction within specific tumor contexts will help identify necessary NK cell modifications and relevant choice of NK cell source. Further enhancement of manufacturing processes will allow for off-the-shelf NK cell immunotherapies to become key components of multifaceted therapeutic strategies for cancer.
Identifiants
pubmed: 33946954
pii: cells10051058
doi: 10.3390/cells10051058
pmc: PMC8146003
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Leukemia. 2018 Feb;32(2):520-531
pubmed: 28725044
Eur J Cell Biol. 2007 Aug;86(8):433-44
pubmed: 17599647
Sci Rep. 2018 May 16;8(1):7675
pubmed: 29769573
Nat Rev Clin Oncol. 2020 Feb;17(2):75-90
pubmed: 31548600
Cytotherapy. 2015 Nov;17(11):1594-603
pubmed: 26341478
Front Oncol. 2019 Feb 11;9:51
pubmed: 30805309
Front Immunol. 2018 Sep 10;9:2041
pubmed: 30250471
Front Immunol. 2018 Sep 20;9:2140
pubmed: 30294328
Hum Vaccin Immunother. 2016 Nov;12(11):2790-2796
pubmed: 27322989
Clin Cancer Res. 2004 Jun 1;10(11):3699-707
pubmed: 15173076
Lancet Oncol. 2018 May;19(5):694-704
pubmed: 29628312
Cancers (Basel). 2019 Jun 23;11(6):
pubmed: 31234588
Pharmacology. 2013;92(1-2):99-107
pubmed: 23949095
J Immunol. 2003 Sep 15;171(6):3034-46
pubmed: 12960329
Front Immunol. 2018 Aug 13;9:1869
pubmed: 30150991
Nat Immunol. 2003 Sep;4(9):882-90
pubmed: 12883552
J Transl Med. 2015 Aug 25;13:277
pubmed: 26303618
Nat Rev Drug Discov. 2015 Jul;14(7):487-98
pubmed: 26000725
Cytotherapy. 2013 Dec;15(12):1563-70
pubmed: 24094496
Blood. 2014 Aug 14;124(7):1081-8
pubmed: 25006133
Bone Marrow Transplant. 2003 Jul;32(2):177-86
pubmed: 12838283
Oncoimmunology. 2017 May 11;6(8):e1320630
pubmed: 28919991
Science. 2011 Jan 7;331(6013):44-9
pubmed: 21212348
Cell Stress Chaperones. 2001 Oct;6(4):337-44
pubmed: 11795470
Cell. 2018 Dec 13;175(7):1731-1743.e13
pubmed: 30503213
Nature. 1998 Feb 19;391(6669):795-9
pubmed: 9486650
J Clin Oncol. 2015 Jan 1;33(1):74-82
pubmed: 25403209
Immunol Rev. 2017 Mar;276(1):80-96
pubmed: 28258692
Eur J Immunol. 2016 May;46(5):1271-8
pubmed: 26840535
PLoS One. 2012;7(1):e30264
pubmed: 22279576
Front Immunol. 2020 Oct 15;11:561553
pubmed: 33178188
Cancer Discov. 2016 Apr;6(4):446-59
pubmed: 26787820
J Clin Oncol. 2008 Apr 20;26(12):2034-9
pubmed: 18347008
Front Immunol. 2020 Jan 09;10:3010
pubmed: 31998304
Cancer Immunol Res. 2019 Mar;7(3):363-375
pubmed: 30651290
Blood. 2009 Jun 11;113(24):6094-101
pubmed: 19365083
Oncotarget. 2016 Oct 11;7(41):66586-66594
pubmed: 27626490
Curr Pharm Des. 2018;24(1):78-83
pubmed: 29283058
Front Immunol. 2018 Apr 16;9:737
pubmed: 29713323
Oncoimmunology. 2017 Feb 7;6(2):e1267892
pubmed: 28344878
Cell. 2016 Oct 6;167(2):419-432.e16
pubmed: 27693353
Blood. 2012 Mar 29;119(13):3064-72
pubmed: 22323453
Front Immunol. 2017 Jun 12;8:676
pubmed: 28659917
J Immunol. 2005 Oct 15;175(8):5541-50
pubmed: 16210663
Front Immunol. 2017 Jun 09;8:654
pubmed: 28649246
Blood Adv. 2020 Nov 24;4(22):5868-5876
pubmed: 33232480
J Hematol Oncol. 2020 Dec 7;13(1):168
pubmed: 33287875
PLoS One. 2010 Feb 15;5(2):e9221
pubmed: 20169160
Cytotherapy. 2017 Feb;19(2):235-249
pubmed: 27887866
J Vis Exp. 2018 Jun 14;(136):
pubmed: 29985369
Mol Cancer Ther. 2012 Dec;11(12):2674-84
pubmed: 23075808
Cell. 2016 Feb 11;164(4):780-91
pubmed: 26830878
Nat Rev Immunol. 2003 Oct;3(10):781-90
pubmed: 14523385
Sci Signal. 2013 Nov 26;6(303):ra102
pubmed: 24280043
Cell Immunol. 1997 Jul 10;179(1):66-73
pubmed: 9259773
Front Immunol. 2016 Mar 14;7:91
pubmed: 27014270
Cell Rep. 2013 Aug 15;4(3):437-44
pubmed: 23933255
Hepatology. 2019 Jul;70(1):168-183
pubmed: 30411378
J Exp Med. 2013 Jun 3;210(6):1167-78
pubmed: 23650441
Hemasphere. 2019 Mar 19;3(2):e188
pubmed: 31723827
J Biol Chem. 2011 Feb 18;286(7):5254-65
pubmed: 21138839
J Immunol Methods. 2003 Aug;279(1-2):79-90
pubmed: 12969549
Exp Hematol. 2010 May;38(5):351-62
pubmed: 20172016
Oncoimmunology. 2015 Dec 21;5(4):e1119354
pubmed: 27141401
Cancer Immunol Res. 2019 Aug;7(8):1371-1380
pubmed: 31239316
Cancer Res. 2013 Mar 15;73(6):1777-86
pubmed: 23302231
J Transl Med. 2005 Apr 14;3(1):15
pubmed: 15831091
Blood. 2005 Jun 1;105(11):4247-54
pubmed: 15728125
Front Immunol. 2020 Feb 13;11:167
pubmed: 32117298
Chem Rev. 2011 Oct 12;111(10):6186-208
pubmed: 21800853
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63
pubmed: 19815499
Cell Med. 2019 Jan 22;11:2155179018822781
pubmed: 32634192
Front Cell Dev Biol. 2016 Sep 07;4:96
pubmed: 27656643
JCI Insight. 2018 Feb 8;3(3):
pubmed: 29415897
Cancers (Basel). 2020 Mar 17;12(3):
pubmed: 32192067
Front Immunol. 2019 Jun 04;10:1242
pubmed: 31214193
J Hematol Oncol. 2021 Jan 6;14(1):7
pubmed: 33407739
Oncotarget. 2017 Apr 4;8(14):23996-24008
pubmed: 28177918
Blood. 2018 Apr 19;131(16):1809-1819
pubmed: 29449276
Blood. 2018 Jan 4;131(1):58-67
pubmed: 29118008
Trends Immunol. 2011 Aug;32(8):364-72
pubmed: 21752715
Br J Haematol. 2005 Jan;128(2):192-203
pubmed: 15638853
Cancer Immunol Immunother. 2010 Dec;59(12):1781-9
pubmed: 20703455
Clin Cancer Res. 2011 Oct 1;17(19):6287-97
pubmed: 21844012
Int J Cancer. 2014 Oct 15;135(8):1832-41
pubmed: 24615391
Semin Immunol. 2017 Jun;31:64-75
pubmed: 28882429
Crit Rev Immunol. 2013;33(2):97-118
pubmed: 23582058
J Immunol. 2008 May 1;180(9):6392-401
pubmed: 18424763
Blood. 2001 Jul 1;98(1):210-6
pubmed: 11418482
Cancer Immunol Res. 2018 Apr;6(4):458-466
pubmed: 29386186
Int J Mol Sci. 2019 Jan 14;20(2):
pubmed: 30646574
Hum Gene Ther Methods. 2012 Dec;23(6):376-86
pubmed: 23186165
Nat Immunol. 2018 Jul;19(7):723-732
pubmed: 29915296
Blood. 2020 Nov 12;136(20):2308-2318
pubmed: 32614951
J Cell Biol. 2020 Sep 7;219(9):
pubmed: 32645139
J Immunother Cancer. 2019 Oct 17;7(1):263
pubmed: 31623687
Front Immunol. 2019 May 31;10:1205
pubmed: 31214177
Front Cell Dev Biol. 2017 Mar 03;5:16
pubmed: 28316970
Cancer Res. 2018 Aug 15;78(16):4692-4703
pubmed: 29967261
Cancer Invest. 2018;36(8):431-457
pubmed: 30325244
Oxid Med Cell Longev. 2017;2017:4629495
pubmed: 29379583
Gynecol Oncol. 2017 Jun;145(3):453-461
pubmed: 28236454
Nat Immunol. 2006 Nov;7(11):1174-81
pubmed: 17028587
Front Pharmacol. 2014 Nov 27;5:254
pubmed: 25505885
Blood. 2012 Dec 6;120(24):4751-60
pubmed: 22983442
Blood. 2005 Jul 1;106(1):376-83
pubmed: 15755898
Curr Opin Immunol. 2017 Feb;44:1-6
pubmed: 27835762
Nat Immunol. 2016 Jul;17(7):816-24
pubmed: 27213690
J Hematol Oncol. 2019 Nov 29;12(1):128
pubmed: 31783889
Cells. 2020 Mar 27;9(4):
pubmed: 32230942
Nature. 2017 Nov 2;551(7678):110-114
pubmed: 29072292
Cell Stress Chaperones. 2000 Nov;5(5):438-42
pubmed: 11189449
J Immunol. 2016 Aug 1;197(3):934-41
pubmed: 27342844
Cytokine. 2011 Dec;56(3):804-10
pubmed: 22019703
Cancers (Basel). 2019 Jul 23;11(7):
pubmed: 31340613
Am J Cancer Res. 2018 Jun 01;8(6):1083-1089
pubmed: 30034945
Sci Rep. 2017 Jan 20;7:39833
pubmed: 28106050
Blood. 2014 Jan 30;123(5):678-86
pubmed: 24326534
Clin Cancer Res. 2009 Aug 1;15(15):4857-66
pubmed: 19638467
Oncoimmunology. 2018 Jul 30;7(11):e1466018
pubmed: 30377559
J Hematol Oncol. 2019 Dec 29;12(1):141
pubmed: 31884955
Cancer Res. 2017 Oct 15;77(20):5664-5675
pubmed: 28790065
Sci Transl Med. 2013 Dec 11;5(215):215ra172
pubmed: 24337479
Clin Cancer Res. 2018 Apr 15;24(8):1834-1844
pubmed: 29444931
Cell Mol Immunol. 2019 May;16(5):430-441
pubmed: 30778167
PLoS One. 2008 May 21;3(5):e2241
pubmed: 18493613
Clin Cancer Res. 2015 Sep 15;21(18):4055-61
pubmed: 25999435
Mol Immunol. 2008 Feb;45(4):1126-35
pubmed: 17714785
Stem Cells. 2018 Feb;36(2):134-145
pubmed: 29235195
J Immunol. 2012 Jun 15;188(12):5990-6000
pubmed: 22573804
Int Immunopharmacol. 2019 Sep;74:105695
pubmed: 31254958
Biochem Biophys Res Commun. 2019 Jul 12;515(1):1-8
pubmed: 30948156
Stem Cell Reports. 2017 Dec 12;9(6):1796-1812
pubmed: 29173894
Blood. 1997 Oct 15;90(8):3098-105
pubmed: 9376591
Mol Ther. 2017 Aug 2;25(8):1769-1781
pubmed: 28668320
Nat Commun. 2016 Feb 17;7:10501
pubmed: 26883990
J Allergy Clin Immunol. 2017 Jan;139(1):335-346.e3
pubmed: 27372564
Nat Commun. 2019 May 7;10(1):2087
pubmed: 31064990
Cell Rep. 2020 Feb 18;30(7):2075-2082.e4
pubmed: 32075731
EBioMedicine. 2020 Sep;59:102975
pubmed: 32853984
Mol Ther. 2017 Jan 4;25(1):274-284
pubmed: 28129121
Front Immunol. 2019 Oct 17;10:2354
pubmed: 31681269
J Biol Chem. 2014 Jun 20;289(25):17647-57
pubmed: 24817116
J Immunol. 2015 Apr 1;194(7):3201-12
pubmed: 25740942
Cell Signal. 2015 Sep;27(9):1731-41
pubmed: 26022178
Cancer Lett. 2020 Mar 1;472:175-180
pubmed: 31790761
Leukemia. 2011 May;25(5):792-9
pubmed: 21274000
J Transl Med. 2013 May 01;11:108
pubmed: 23634660
Clin Cancer Res. 2018 Nov 15;24(22):5552-5561
pubmed: 30045932
Clin Cancer Res. 2014 Aug 15;20(16):4262-73
pubmed: 24919573
Blood. 2017 Oct 19;130(16):1857-1868
pubmed: 28835441
Front Immunol. 2016 Apr 21;7:152
pubmed: 27148271
BMB Rep. 2021 Jan;54(1):44-58
pubmed: 33298244
Biochem Pharmacol. 2017 Jan 1;123:29-39
pubmed: 27974147
Nat Rev Clin Oncol. 2020 Mar;17(3):147-167
pubmed: 31848460
Immunohorizons. 2018 Apr 1;2(4):107-118
pubmed: 30027154
Cell Stem Cell. 2020 Aug 6;27(2):224-237.e6
pubmed: 32531207
Semin Immunopathol. 2019 Jan;41(1):59-68
pubmed: 30361801
Immunol Rev. 2007 Dec;220:169-82
pubmed: 17979846
Cell Stem Cell. 2018 Aug 02;23(2):181-192.e5
pubmed: 30082067
Cancer Immunol Immunother. 2012 Sep;61(9):1451-61
pubmed: 22310931
Br J Haematol. 1996 Mar;92(4):788-94
pubmed: 8616068
Cancer Res. 1998 Apr 15;58(8):1695-9
pubmed: 9563485
Front Immunol. 2019 Aug 21;10:1999
pubmed: 31552017
Eur J Immunol. 2008 Jun;38(6):1621-30
pubmed: 18493981
Nat Immunol. 2014 May;15(5):431-8
pubmed: 24658051
J Clin Oncol. 2012 Sep 20;30(27):3396-401
pubmed: 22915661
Clin Sci (Lond). 2020 Jul 17;134(13):1637-1658
pubmed: 32608491
J Immunol. 2004 Jan 15;172(2):972-80
pubmed: 14707070
Methods Mol Biol. 2016;1441:277-84
pubmed: 27177674
Cancer Immunol Res. 2018 Feb;6(2):209-221
pubmed: 29321210
Blood. 2012 Nov 22;120(22):4317-23
pubmed: 23002117
J Immunol. 2009 Dec 1;183(11):6939-47
pubmed: 19915047
EBioMedicine. 2017 Aug;22:44-57
pubmed: 28750861
J Immunol. 2006 Feb 1;176(3):1582-7
pubmed: 16424187
J Lipid Res. 2016 Mar;57(3):368-79
pubmed: 26768655
Front Immunol. 2020 Aug 07;11:1965
pubmed: 32903482
Front Immunol. 2019 Dec 03;10:2816
pubmed: 31849984